Drug treatment programsPrisonsRecidivismSubstance abuseMenWomenResearch programsThe Federal Bureau of Prisons (BOP) has provided drug abuse treatment in various forms for almost two decades. The current residential drug abuse treatment programs (DAP) were developed following passage of the Anti-Drug Abuse...
(DATOS) 1-year and 5-year followups were used to describe the long-term outcomes of drug treatment and to further clarify the relationship between treatment duration and post-treatment outcomes in four treatment modalities: outpatient methadone, long-term residential (LTR), outpatient drug free (...
Male gender, normal nutritional status, non-presumed drug resistance to TB, and HIV-negative status were significantly associated with successful TB treatment outcomes. By taking risk factors associated with poor treatment outcomes like those found in this study into account, patient management and ...
Chitotriosidase activity has been shown to correlate with several clinical parameters of GD as well as to decline in response to treatment. Chitotriosidase was the first biomarker used in GD. However, apart from a 17-year-long observation of chitotriosidase in 55 GD type 1 Romanian patients...
indicated that a 5-day course of the drug did not significantly improve symptom resolution time compared with placebo in this specific patient population. “Although some interest persists in use of ivermectin as a possible treatment for COVID-19, decisions regarding this drug must be based on ri...
cohort demonstrated significant reduction in weight at 8 weeks. Across both cohorts, GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks and low study discontinuation rates due to adverse events related to study drug (2.8% in T2DM and ...
Comorbid conditions and adverse drug events are associated with poor treatment outcomes among patients with drug resistant tuberculosis (DR – TB). This study aimed at determining the treatment outcomes of DR – TB patients with poor prognostic indicators in Uganda. Methods We reviewed treatment record...
advanced two unique drug candidates, zelnecirnon (RPT193) and tivumecirnon (FLX475), each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery s...
Food and Drug Administration (FDA) in December 2022. The Company is utilizing a priority review voucher in connection with the submission. EYLEA (aflibercept) Injection In December 2022, the European Commission (EC) approved EYLEA for the treatment of retinopathy of prematurity (...
摘要: ObjectiveTo describe the use of the LUNDEX, a new index for comparing the long-term efficacy and tolerability of biologic therapies in rheumatoid arthritis (RA) patients treated in clinical practice.DOI: 10.1002/art.21570 被引量: 127 ...